🔎 Trials Near Me

Utama › Leukemia Biphenotipik Akut › New York

Kajian klinikal Leukemia Biphenotipik Akut di New York

11 kajian untuk Leukemia Biphenotipik Akut sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 1
Umur 12 hingga 78 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Albany Medical Center, Albany
  • Roswell Park Cancer Institute, Buffalo
  • The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
  • dan 7 lagi
Mengambil pesertaFasa 2
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Montefiore Medical Center, New York
Mengambil pesertaFasa 1/2
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • Roswell Park Cancer Institute, Buffalo
  • dan 12 lagi
Mengambil pesertaFasa 3
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • NYU Langone Hospital - Long Island, Mineola
  • dan 7 lagi
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • New York Medical College, Valhalla
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Memorial Sloan- Kettering Cancer Center, New York
Mengambil pesertaFasa 1
Umur 1 hingga 30 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06177067

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Weill Cornell Medicine - New York Presbyterian Hospital, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07216443

A Study of Revumenib and Mezigdomide in People With Leukemia

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • dan 1 lagi
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT07356154

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

  • Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 1
Umur 12 ke atas · Semua jantina · Dikemas kini 8 Jan 2026 · NCT04872478

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital New York-Presbyterian, New York
  • Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 1
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.